<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04519047</url>
  </required_header>
  <id_info>
    <org_study_id>201812157DSA</org_study_id>
    <nct_id>NCT04519047</nct_id>
  </id_info>
  <brief_title>IA Injection of Rejoint Gel and PRP in Patients With Unilateral Knee OA</brief_title>
  <official_title>A Randomized, Double-blind, Feasibility Study to Evaluate the Safety and Potential for Effectiveness of Intra-articular Injection of Rejoint Gel After Platelet-rich Plasma Administration in Patients With Unilateral Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Industrial Technology Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and tolerability of intra-articular Injection doses of Rejoint Gel after&#xD;
      platelet-rich plasma administration in unilateral knee OA subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single-center, randomized, double-blind, feasibility study to evaluate the safety and&#xD;
      potential for effectiveness of an intraarticular Injection of Rejoint Gel after platelet-rich&#xD;
      plasma administration in patient with single knee OA, parallel-design study will enroll&#xD;
      approximately eligible 30 subjects with single knee OA.&#xD;
&#xD;
      The subjects will be randomized (1:1) to receive 1 of 2 treatments below:&#xD;
&#xD;
        1. Treatment Group: Rejoint Gel, intra-articular injection, with platelet-rich plasma (PRP)&#xD;
           in 2:1 volume ratio or&#xD;
&#xD;
        2. Control Group: Normal saline, intra-articular injection with PRP in 2:1 volume ratio&#xD;
           Beginning on treatment period, subjects will receive a single treatment cycle of either&#xD;
           150 mg/ml Rejoint Gel or normal saline with PRP intra-articular injection twice for one&#xD;
           month (Visit 3 and 4). Subjects will be followed to Visit 5, 6 and 7 for safety and&#xD;
           potential for effectiveness assessments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse events (AEs) and serious AEs</measure>
    <time_frame>Baseline to Visit 7 (15th week)</time_frame>
    <description>Adverse events (AEs) and serious AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Western Ontario and McMaster Universities Index for osteoarthritis</measure>
    <time_frame>Baseline to Visit 7 (15th week)</time_frame>
    <description>Change in Western Ontario and McMaster Universities (WOMAC) Index for osteoarthritis: five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68). Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kellgren-Lawrence grading scale</measure>
    <time_frame>Baseline to Visit 7 (15th week)</time_frame>
    <description>Change in the Kellgren-Lawrence (KL) Grading Scale: 0-IV (0: normal, IV: the worst)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>PRP</condition>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Rejoint</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rejoint+PRP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Saline+PRP</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRP</intervention_name>
    <description>Beginning on treatment period, subjects will receive either Rejoint Gel or normal saline with PRP intra-articular injection twice for one month (Visit 3 and 4).</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Rejoint</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Written informed consent before any study-specific procedure is performed;&#xD;
&#xD;
          2. Ages of 45~80 years old on the day of consent;&#xD;
&#xD;
          3. The patient is able to understand the nature of the study;&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2;&#xD;
&#xD;
          5. Patient was diagnosed as OA of single knee joint by American College of Rheumatology&#xD;
             (ACR) criteria; [i.e, knee pain, and any one of the following: age&gt; 45 years,&#xD;
             crepitus, or morning stiffness&lt;30 minutes in duration, or confirmed through&#xD;
             radiographic X ray];&#xD;
&#xD;
          6. Knee WOMAC Pain Score (sum of five components) between 20 and 40 score, after 15&#xD;
             meters of walking pain;&#xD;
&#xD;
          7. Contralateral knee WOMAC Pain Score &lt;15 score;&#xD;
&#xD;
          8. Never receiving intra-articular hyaluronic acid (HA) injections of the knee, or last&#xD;
             received intra-articular HA more than 6 months;&#xD;
&#xD;
          9. Patient meets below conditions by blood test, kidney and liver function test :&#xD;
&#xD;
        White blood cell (WBC) count &gt; 3,000/μL Absolute neutrophil count (ANC) ≥ 1,500/μL&#xD;
        Hemoglobin (Hb) ≥ 9.0 g/dL Thrombocyte count &gt; 50,000/μL Blood urea nitrogen (BUN) and&#xD;
        serum Creatinine ≤ 3X Upper Limit of Normal (ULN) Aspartate aminotransferase (AST) and&#xD;
        Alanine aminotransferase (ALT) ≤ 3 x ULN&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Known sensitivity to mPEG-PLGA hydrogel (Rejoint Gel);&#xD;
&#xD;
          2. Infection in the joint or surrounding skin;&#xD;
&#xD;
          3. Known Intra-articular neoplasm;&#xD;
&#xD;
          4. Inflammatory joint disease, OA in the hips, osteonecrosis, moderate to marked effusion&#xD;
             from index knee;&#xD;
&#xD;
          5. Documented current positive synovial fluid culture;&#xD;
&#xD;
          6. Large knee circumference (&gt;45 cm);&#xD;
&#xD;
          7. History of herpes zoster in the past 3 months;&#xD;
&#xD;
          8. Last receiving the treatment of immunosuppressants, anti-coagulants, Non-steroidal&#xD;
             anti-inflammatory Drugs (NSAIDs), antidepressants 14 days prior to study&#xD;
             randomization;&#xD;
&#xD;
          9. Planned knee surgery in the next 6 months or received knee surgery in the past 6&#xD;
             months;&#xD;
&#xD;
         10. Subject is receiving or is less than 28 days since ending other investigational device&#xD;
             or drug;&#xD;
&#xD;
         11. Known full-thickness cartilage loss in index knee;&#xD;
&#xD;
         12. Documented fibromyalgia, or hemiparesis;&#xD;
&#xD;
         13. Evidence of signs or symptoms of a viral, bacterial, or fungal infection occur 14 days&#xD;
             prior to the study treatment starts, per the assessment of the investigator;&#xD;
&#xD;
         14. Any major medical or psychiatric disorder that in the opinion of the investigator,&#xD;
             might prevent the subject from completing the study or interfere with the&#xD;
             interpretation of the study results, such as terminal diseases, malignant tumors,&#xD;
             heart failure (NYHA II-IV), coronary arterial disease, uncontrolled hypertension,&#xD;
             uncontrolled diabetes, peripheral arterial disease or dementia, might prevent the&#xD;
             subject from completing the study or interfere with the interpretation of the study&#xD;
             results;&#xD;
&#xD;
         15. Pre-menopausal females of childbearing potential not willing to use acceptable&#xD;
             method(s) of birth control during treatment;&#xD;
&#xD;
         16. Female subject who is lactating or pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chueh-Hung Wu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chueh-Hung Wu, MD, PhD</last_name>
    <phone>+886223123456</phone>
    <phone_ext>66473</phone_ext>
    <email>nojred@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chueh-Hung Wu, MD, PhD</last_name>
      <phone>886223123456</phone>
      <phone_ext>66473</phone_ext>
      <email>nojred@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 16, 2020</study_first_submitted>
  <study_first_submitted_qc>August 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>August 20, 2020</last_update_submitted>
  <last_update_submitted_qc>August 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PRP</keyword>
  <keyword>Knee Osteoarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

